Artelo Biosciences Inc Asset Resilience Ratio
Artelo Biosciences Inc asset resilience ratio. Artelo Biosciences Inc (ARTL) has an Asset Resilience Ratio of 0.00% as of December 2024. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. See Artelo Biosciences Inc defensive liquidity buffer to measure how many days the company can operate on defensive assets alone.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio of Artelo Biosciences Inc (2019–2024)
Asset resilience ratio of Artelo Biosciences Inc from 2019 to 2024. This chart shows how Artelo Biosciences Inc's Asset Resilience Ratio has changed over time. Read ARTL current and long-term liabilities for a breakdown of total debt and financial obligations.
Liquid Assets Composition Over Time
This chart breaks down Artelo Biosciences Inc's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For the complete balance sheet picture, see balance sheet size of Artelo Biosciences Inc.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 0% |
| Short-term Investments | $0.00 | 0% |
| Total Liquid Assets | $0.00 | 0.00% |
Asset Resilience Insights
- Limited Liquidity: Artelo Biosciences Inc maintains only 0.00% of assets in liquid form.
- This low level may indicate efficient asset utilization but could pose risks during economic downturns.
- The company maintains a balanced mix of cash and short-term investments.
Artelo Biosciences Inc Industry Peers by Asset Resilience Ratio
Compare Artelo Biosciences Inc's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Hyloris Developmentsen Sa
BR:HYL |
Biotechnology | 1.36% |
|
Biomarin Pharmaceutical Inc
NASDAQ:BMRN |
Biotechnology | 0.00% |
|
Oruka Therapeutics, Inc.
NASDAQ:ORKA |
Biotechnology | 53.11% |
|
Gempharmatech Co. Ltd. A
SHG:688046 |
Biotechnology | 23.95% |
|
Vor Biopharma Inc
NASDAQ:VOR |
Biotechnology | 74.48% |
|
Inventiva S.A
PA:IVA |
Biotechnology | 52.73% |
|
Sunmax Biotechnology Co Ltd
TWO:4728 |
Biotechnology | 10.53% |
|
Guangdong VTR Bio-Tech Co Ltd
SHE:300381 |
Biotechnology | 4.98% |
Artelo Biosciences Inc Asset Resilience Ratio by Year (2019–2024)
Artelo Biosciences Inc asset resilience ratio by year from 2019 to 2024. The table below shows the annual Asset Resilience Ratio data for Artelo Biosciences Inc.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2024-12-31 | 0.00% | $0.00 | $4.70 Million | -- |
| 2023-12-31 | 58.35% | $7.61 Million | $13.04 Million | +6.23pp |
| 2022-12-31 | 52.12% | $10.64 Million | $20.42 Million | +24.93pp |
| 2021-12-31 | 27.19% | $3.44 Million | $12.63 Million | -- |
| 2020-12-31 | 0.00% | $0.00 | $4.38 Million | -- |
| 2019-12-31 | 0.02% | $1.50K | $6.48 Million | -- |
About Artelo Biosciences Inc
Artelo Biosciences, Inc., a clinical stage biopharmaceutical company, develops and commercializes therapeutics that target lipid-signaling pathways in the United States. The company's product candidate pipeline includes ART27.13, a synthetic dual cannabinoid G protein-coupled receptor agonist, which is in Phase 1b/2a clinical trial for the treatment of cancer-related anorexia; and ART12.11, a coc… Read more